Navigation Links
The 'febit science lounge' presents: Webinar About Role of Non-Protein-Coding RNA in Human Genome Set for 11 a.m. EDT on June 12
Date:6/5/2008

'The human genome as an RNA machine' with Prof. John Mattick with Institute

for Molecular Bioscience at University of Queensland, Australia

LEXINGTON, Mass. and HEIDELBERG, Germany, June 5 /PRNewswire/ -- febit holding gmbh today unveiled plans for the first of a series of educational Webinars geared for genomics researchers worldwide.

Moderated by febit's chief scientific officer, Peer Staehler, the first Webinar, which is set for 11 a.m. EDT on June 12, will feature John Mattick, Ph.D., a world-renowned researcher whose focus is the role of non-protein-coding ("junk") RNA in relation to the evolution and development of complex organisms.

"Genetic information that programs complex organisms lie in non-protein coding RNA," said Dr. Mattick, foundation professor of molecular biology and director of the Centre for Molecular Biology and Biotechnology, with the Institute for Molecular Bioscience at the University of Queensland, Australia. "This massive hidden network of regulatory information directs the precise patterns of gene expression during growth and development."

Mr. Staehler added: "This educational Webinar for the genomics researchers is the first of many to come. The team at febit is dedicated to support researchers to solve the challenge of understanding biological processes."

To participate in the Webinar, register at http://www.febit.com. Please connect to the Webinar several minutes prior to the start time to ensure adequate time for any software download that may be necessary. The live event may also be accessed by dialing 877-715-5318 (for U.S. callers) and 973-582-2852 (for international callers) and entering conference ID 50057678. Questions may be asked over the telephone during the live event or e-mailed in advance to webinar@febit.com. The Webinar will be available for replay for one year on febit's Web site.

About febit

febit enables scientists to read, write and understand the code of life: DNA. With its unique Geniom technology and services, febit is the only company that puts the control of simplified genomic research in the hand of the user. The seamless integration of DNA synthesis and analysis and the superior support in experiment design and bioinformatics helps to understand data and turn it into results. febit's team of experienced scientists is dedicated to support customers to solve the challenge of understanding biological processes. Geniom is a technological and service platform successfully implemented in basic and applied research by renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes, providing superior time- and cost-efficiency combined with an unsurpassed spectrum of applications.

http://www.febit.com

Contact:

febit holding gmbh Russo Partners, LLC

Eva Sterzel David Schull or Wendy Lau

Public Relations Manager +1-212-845-4271

+49 (6221) 6510-300 david.schull@russopartnersllc.com

eva.sterzel@febit.de wendy.lau@russopartnersllc.com


'/>"/>
SOURCE febit
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
2. Penn scientist receives LOréal USA fellowship for women in science
3. Edwards Lifesciences to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
4. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming WUWHS Conference
5. Medical Simulation Corporation Announces Partnership With Seattle Science Foundation
6. Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line
7. New federally-funded health initiative to speed benefits of science to North Carolinians
8. Harvard Medical School receives major NIH grant for galvanizing translational science
9. BUMC, BMC receives Clinical and Translational Science Award from NIH
10. Experts to discuss sleep science and the health risks of sleep disorders in Baltimore this June
11. 1 small step for a lab science, 1 green leap for mankind
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: